Nitemazepam

Benzodiazepine designer drug
  • CA: Schedule IV
  • DE: NpSG (Industrial and scientific use only)
  • UK: Under Psychoactive Substances Act
Identifiers
  • 7-nitro-3-hydroxy-5-phenyl-1-methyl-1H-benzo[e] [1,4]diazepin-2(3H)-one
CAS Number
  • 40762-03-6
PubChem CID
  • 12362353
ChemSpider
  • 64854354
UNII
  • DFJ6M9363O
Chemical and physical dataFormulaC16H13N3O4Molar mass311.297 g·mol−13D model (JSmol)
  • Interactive image
  • O=[N+](O)c1ccc2c(c1)C(=NC(O)C(=O)N2C)c3ccccc3
InChI
  • InChI=1S/C16H13N3O4/c1-18-13-8-7-11(19(22)23)9-12(13)14(17-15(20)16(18)21)10-5-3-2-4-6-10/h2-9,15,20H,1H3
  • Key:QRWVNMAJJIQCEG-UHFFFAOYSA-N

Nitemazepam (or 3-hydroxynimetazepam) is a benzodiazepine derivative which was first synthesised in the 1970s but was never marketed. It is the 7-nitro instead of 7-chloro analogue of temazepam, and also the 3-hydroxy derivative of nimetazepam, and an active metabolite. It has in more recent years been sold as a designer drug, first being definitively identified in Europe in 2017. It is metabolized to 7-aminonitemazepam, nimetazepam, 3-hydroxynitemazepam, temazepam, and nimetazepam glucuronide.[1][2]

References

  1. ^ Zawilska JB, Wojcieszak J (July 2019). "An expanding world of new psychoactive substances-designer benzodiazepines". Neurotoxicology. 73: 8–16. doi:10.1016/j.neuro.2019.02.015. PMID 30802466. S2CID 73461430.
  2. ^ Moosmann B, Auwärter V (2018). "Designer Benzodiazepines: Another Class of New Psychoactive Substances.". In Maurer H, Brandt S (eds.). New Psychoactive Substances. Handbook of Experimental Pharmacology. Vol. 252. pp. 383–410. doi:10.1007/164_2018_154. ISBN 978-3-030-10560-0. PMID 30367253.
  • v
  • t
  • e
1,4-Benzodiazepines
1,5-Benzodiazepines2,3-Benzodiazepines*TriazolobenzodiazepinesImidazobenzodiazepinesOxazolobenzodiazepinesThienodiazepinesThienotriazolodiazepinesThienobenzodiazepines*PyridodiazepinesPyridotriazolodiazepinesPyrazolodiazepinesPyrrolodiazepinesTetrahydroisoquinobenzodiazepinesPyrrolobenzodiazepines*Benzodiazepine prodrugs
* atypical activity profile (not GABAA receptor ligands)
  • v
  • t
  • e
GABAA
Alcohols
Barbiturates
Benzodiazepines
Carbamates
Imidazoles
Monoureides
Neuroactive steroids
Nonbenzodiazepines
Phenols
Piperidinediones
Quinazolinones
Others
GABAB
H1
Antihistamines
Antidepressants
Antipsychotics
α2-Adrenergic
5-HT2A
Antidepressants
Antipsychotics
Others
Melatonin
Orexin
α2δ VDCC
Others
  • v
  • t
  • e
GABAA receptor positive modulators
Alcohols
Barbiturates
Benzodiazepines
Carbamates
Flavonoids
Imidazoles
Kava constituents
  • 10-Methoxyyangonin
  • 11-Methoxyyangonin
  • 11-Hydroxyyangonin
  • Desmethoxyyangonin
  • 11-Methoxy-12-hydroxydehydrokavain
  • 7,8-Dihydroyangonin
  • Kavain
  • 5-Hydroxykavain
  • 5,6-Dihydroyangonin
  • 7,8-Dihydrokavain
  • 5,6,7,8-Tetrahydroyangonin
  • 5,6-Dehydromethysticin
  • Methysticin
  • 7,8-Dihydromethysticin
  • Yangonin
Monoureides
Neuroactive steroids
Nonbenzodiazepines
Phenols
Piperidinediones
Pyrazolopyridines
Quinazolinones
Volatiles/gases
Others/unsorted
  • Unsorted benzodiazepine site positive modulators: α-Pinene
  • MRK-409 (MK-0343)
  • TCS-1105
  • TCS-1205
See also: Receptor/signaling modulators • GABA receptor modulators • GABA metabolism/transport modulators